Parkinsonism & Related Disorders
Volume 15, Issue 9 , Pages 649-654 , 5 November 2009

A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human α-synuclein A30P+A53T transgenic mice

  • Kazuhiko Ono

      Affiliations

    • Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 92 871 6631; fax: +81 92 863 0389.
    • ,
  • Miyuki Ikemoto

      Affiliations

    • Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
    • ,
  • Takeshi Kawarabayashi

      Affiliations

    • Department of Neurology, Institute of Brain Science, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan
    • ,
  • Masaki Ikeda

      Affiliations

    • Department of Neurology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan
    • ,
  • Takuya Nishinakagawa

      Affiliations

    • Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
    • ,
  • Masato Hosokawa

      Affiliations

    • Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
    • ,
  • Mikio Shoji

      Affiliations

    • Department of Neurology, Institute of Brain Science, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan
    • ,
  • Mitsuo Takahashi

      Affiliations

    • Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
    • ,
  • Manabu Nakashima

      Affiliations

    • Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan

Received 18 November 2008 ,Revised 6 March 2009 ,Accepted 10 March 2009.

References 

  1. Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, Hatano T, et al. Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci. 2008;363(1500):2215–2227
  2. Iwatsubo T. Aggregation of α-synuclein in the pathogenesis of Parkinson's disease. J Neurol. 2003;250(Suppl 3):III11–III14
  3. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, et al. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem. 2005;280(9):7800–7807
  4. Tanaka M, Kim YM, Lee G, Juun E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem. 2004;279(6):4625–4631
  5. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a drosophila model of Parkinson's disease. Nat Neurosci. 2005;8(5):657–663
  6. Klucken J, Shin Y, Maslia E, Hyman BT, Mclean PJ. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem. 2004;279(24):25497–25502
  7. Lo Bianco C, Shorter J, Régulier E, Lashuel H, Iwatsubo T, Lindquist S, et al. Hsp104 antagonizes α-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest. 2008;118(9):3087–3097
  8. Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med. 1996;335(12):855–859
  9. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995;85(1):43–49
  10. Mercuri E, Bertini E, Messina S, Pelliccioni M, D'Amico A, Colotto F, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord. 2004;14(2):130–135
  11. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res. 2001;7(10):3047–3055
  12. Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med. 2004;5(3):235–241
  13. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem. 2005;280(1):556–563
  14. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93(5):1087–1098
  15. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitripsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A. 2000;97(4):1796–1801
  16. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc 70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol. 2000;278(2):C259–C267
  17. Kubota K, Niinuma Y, Kaneko M, Okuma Y, Sugai M, Omura T, et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem. 2006;97(5):1259–1268
  18. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137–1140
  19. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci. 2007;48(4):1683–1690
  20. de Almeida SF, Picarote G, Fleming JV, Carmo-Fonseca M, Azevedo JE, de Sousa M. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem. 2007;282(38):27905–27912
  21. Inden M, Kitamura Y, Takeuchi H, Yanagita T, Takata K, Kobayashi Y, et al. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem. 2007;101(6):1491–1504
  22. Ikeda M, Kawarabayashi T, Harigaya Y, Sasaki A, Matsubara E, Murakami T, et al. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology. Brain Res. 2009;1250:232–241
  23. Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, et al. Brain pericytes contribute to the induction and up-regulation of blood–brain barrier functions through transforming growth factor-β production. Brain Res. 2005;1038(2):208–215
  24. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol. 1985;50(3):435–441
  25. Ikeda T, Mishima K, Yoshikawa T, Iwasaki K, Fujiwara M, Xia YX, et al. Selective and long-term learning impairment following neonatal hypoxic–ischemic brain insult in rats. Behav Brain Res. 2001;118(1):17–25
  26. Veszelka S, Urbányi Z, Pázmány T, Németh L, Obál I, Ábrahám CS, et al. Human serum amyloid P component attenuates the bacterial lipopolysaccharide-induced increase in blood–brain barrier permeability in mice. Neurosci Lett. 2003;352(1):57–60
  27. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, et al. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro-Oncol. 2005;7(2):177–182
  28. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah EE, Goldberg MS, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4(2):160–164
  29. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292–1295
  30. Papp E, Csermely P. Chemical chaperones: mechanisms of action and potential use. Handb Exp Pharmacol. 2006;172:405–416

PII: S1353-8020(09)00064-9

doi: 10.1016/j.parkreldis.2009.03.002

Parkinsonism & Related Disorders
Volume 15, Issue 9 , Pages 649-654 , 5 November 2009

Article Tools

* Image Usage & Resolution